Home
About Journal
Editorial Board
Instruction
Subscribe
Download
Contact Us
Chinese
中国医学创新
2025
,
Vol. 22
Issue (13)
: 16-20
DOI
: 10.3969/j.issn.1674-4985.2025.13.004
Article
Current Issue
|
Archive
|
Adv Search
|
Trastuzumab + Paclitaxel and Epirubicin in the Treatment of HER2 Positive Breast Cancer
LIU Xiaoying
First-author's address: Department of Pharmacy, Nanchang People's Hospital, Nanchang 330002, China
Abstract
Figure/Table
References
Related Citation (15)
Download:
PDF
(997 KB)
HTML
(1 KB)
Export:
BibTeX
|
EndNote
(RIS)
Received:
02 September 2024
Service
E-mail this article
Add to my bookshelf
Add to citation manager
E-mail Alert
RSS
Articles by authors
LIU Xiaoying
Cite this article:
LIU Xiaoying. Trastuzumab + Paclitaxel and Epirubicin in the Treatment of HER2 Positive Breast Cancer[J]. 中国医学创新, 2025, 22(13): 16-20.
URL:
http://www.zgyxcx.com/EN/10.3969/j.issn.1674-4985.2025.13.004
OR
http://www.zgyxcx.com/EN/Y2025/V22/I13/16
[1]
ZHAO Gang,PEI Yawei.
The Impact of Transurethral Resection of Bladder Tumor Combined with Epirubicin Hyperthermic Intravesical Chemotherapy on Prognosis in Non-Muscle-Invasive Bladder Cancer
[J]. 中国医学创新, 2025, 22(9): 1-5.
© 2016 中国医学创新 editorial
Address: Beijing south cellular road number five Postcodes: 100055